Investigation of the in vitro activities of various antibiotics against Brucella melitensis strains;Çeşitli antibiyotiklerin Brucella melitensis suşlarına karşı in vitro etkinliklerinin araştırılması

Turkish Journal of Medical Sciences

Volumn 42, Issue 1, 2012, Pages 145-148

  Kaya, Onur ^a   Akçam, Füsun Zeynep ^a   Yayli, Güler ^a  

^a SULEYMAN DEMIREL UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Brucella; MIC; Susceptibility

Indexed keywords

ANTIBIOTIC AGENT; CEFTRIAXONE; CIPROFLOXACIN; DOXYCYCLINE; LEVOFLOXACIN; RIFAMPICIN; STREPTOMYCIN; TETRACYCLINE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BLOOD SAMPLING; BROTH DILUTION; BRUCELLA MELITENSIS; BRUCELLOSIS; HAEMOPHILUS; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

EID: 84055197741     PISSN: 13000144     EISSN: None     Source Type: Journal    
DOI: 10.3906/sag-1009-1129     Document Type: Article

References (20)

1. Pappas G, Papadimitriou P, Akritidis N, Christou L, Tsianos EV. The new global map of human brucellosis. Lancet Infect Dis 2006; 6: 91-9.
2. Buzgan T, Karahocagil MK, Irmak H, Baran AI, Karsen H, Evirgen O et al. Clinical manifestations and complications in 1028 cases of brucellosis: a retrospective evaluation and review of the literature. Int J Infect Dis 2010; 14: 469-78.
3. Young EJ. Brucella species. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 7th ed. Philadelphia (PA): Churchill Livingstone; 2010. p.2921-5.
4. Solera J. Update on brucellosis: therapeutic challenges. Int J Antimicrob Agents 2010; 36: S18-20.
5. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: 19th informational supplement. CLSI Document M100-S19. Wayne (PA): CLSI, 2009.
6. Food and Agriculture Organization, WHO. Joint FAO-WHO Expert Committee on Brucellosis, sixth report. In: World Health Organization Technical Report Series 740. Geneva: WHO; 1986.
7. Eşel D, Sümerkan B, Ayangil D, Telli M. Brucella melitensis suşlari{dotless}ni{dotless}n antibiyotik duyarli{dotless}li{dotless}klari{dotless}ni{dotless}n belirlenmesinde agar dilüsyon ve E-test yöntemlerinin karşi{dotless}laşti{dotless}ri{dotless}lmasi{dotless}. Ankem Derg 2004; 18: 196-9.
8. Baykam N, Esener H, Ergönül Ö, Eren Ş, Çelikbas AK, Dokuzoǧuz B. In vitro antimicrobial susceptibility of Brucella species. Int J Antimicrob Agents 2004; 23: 405-7.
9. Turan H, Arslan H, Uncu H, Azap Ö, Şerefh anoǧlu K. Tigesiklinin Brucella suşlari{dotless}na in vitro etkinliǧinin doksisiklin, siprofloksasin ve rifampisinin etkinliǧi ile karşi{dotless}laşti{dotless}ri{dotless}lmasi{dotless}. İnfeksiyon Dergisi 2007; 21: 147-51.
10. Ayaşli{dotless}oǧlu E, Ki{dotless}li{dotless}ç S, Aydi{dotless}n K, Ki{dotless}li{dotless}ç D, Kaygusuz S, Aǧalar C. Antimicrobial susceptibility of Brucella melitensis isolates from blood samples. Turk J Med Sci 2008; 38: 257-62.
11. Bodur H, Balaban N, Aksaray S, Yetener V, Akinci E, Colpan A et al. Biotypes and antimicrobial susceptibilities of Brucella isolates. Scand J Infect Dis 2003; 35: 337-8.
12. Turkmani A, Ioannidis A, Christidou A, Psaroulaki A, Loukaides F, Tselentis Y. In vitro susceptibilities of Brucella melitensis isolates to eleven antibiotics. Ann Clin Microbiol Antimicrob 2006; 5: 24.
13. Bosch J, Linares J, Lopez de Goicoechea MJ, Ariza J, Cisnal MC, Martin R. In-vitro activity of ciprofloxacin, ceft riaxone and five other antimicrobial agents against 95 strains of Brucella melitensis. J Antimicrob Chemother 1986; 17: 459-61.
14. Trujillano-Martin I, Garcia-Sanchez E, Martinez IM, Fresnadillo MJ, Garcia-Sanchez JE, Garcia-Rodriguez JA. In vitro activities of six new fluoroquinolones against Brucella melitensis. Antimicrob Agents Chemother. 1999; 43: 194-5.
15. Akova M, Gür D, Livermore DM, Kocagöz T, Akalin HE. In vitro activities of antibiotics alone and in combination against Brucella melitensis at neutral and acidic pHs. Antimicrob Agents Chemother 1999; 43: 1298-300.
16. Memish Z, Mah MW, Al Mahmoud S, Al Shaalan M, Khan MY. Brucella bacteraemia: clinical and laboratory observations in 160 patients. J Infect 2000; 40: 59-63.
17. Akova M, Uzun Ö, Akalin HE, Hayran M, Ünal S, Gür D. Quinolones in treatment of human brucellosis: comparative trial of ofloxacin-rifampin versus doxycycline-rifampin. Antimicrob Agents Chemother 1993; 37: 1831-4.
18. Agalar C, Usubutun S, Turkyilmaz R. Ciprofloxacin and rifampicin versus doxycycline and rifampicin in the treatment of brucellosis. Eur J Clin Microbiol Infect Dis 1999; 18: 535-8.
19. Kocagöz S, Akova M, Altun B, Gür D, Hasçelik G. In vitro activities of new quinolones against Brucella melitensis isolated in a tertiary-care hospital in Turkey. Clin Microbiol Infect 2002; 8: 240-2.
20. Rubinstein E, Lang R, Shasha B, Hagar B, Diamanstein L, Joseph G et al. In vitro susceptibility of Brucella melitensis to antibiotics. Antimicrob Agents Chemother 1991; 35: 1925-7.